ASH 2023 | The treatment of AML within the United Kingdom NHS framework
Jad Othman
• 11 Dec 2023
Jad Othman, MBBS, King’s College and Guy’s & St Thomas’ NHS Foundation Trust, London, UK, outlines the standard treatment protocol for patients with acute myeloid leukemia (AML) treated within the UK National Health Service (NHS). Patients receive double induction therapy followed by two consolidation treatments, often within the framework of a UK NCRI trial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
